Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nippon Shinyaku Co., Ltd.

https://www.nippon-shinyaku.co.jp/english/

Latest From Nippon Shinyaku Co., Ltd.

With 2023's Largest Indian IPO, Mankind Listing Watched; GPCR-Based Candidate Enters Trials

Scrip takes a look at what a listing of Mankind Pharma, which has thrice the revenues of Pfizer’s India unit and the fourth largest domestic pharma sales, would mean. A GPCR-based candidate against type-2 diabetes and obesity is in Phase I trials and a search on India’s trial registry reveals a study for an ayurvedic preparation against diabetes

Commercial Financing

China Pharma Embraces AI Tools Amid Globalization Challenges

The Chinese biopharma industry is eager to use the latest artificial intelligence technology to boost efficiency and lighten workloads, as companies deal with drastic change and look to improve their understanding of foreign markets. Meanwhile, senior European leaders called for a level playing field during a recent visit to China.

China Artificial Intelligence

China Pharma Eyes Brighter SE Asia Markets Amid US Entry Shadows

Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.

Asia Pacific Deals

China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer

CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.

China Vaccines
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • NS Pharma, Inc.
    • Tianjin Nippon Shinyaku Co., Ltd.
    • Tianjin NS
UsernamePublicRestriction

Register